 "Dr Reddy's Q1 net down 76% at Rs 154 cr")
Dr Reddy’s Laboratories Ltd has launched bivalirudin for injection (250 mg per vial), which has been approved by the US Food and Drug Administration (FDA). The product is a generic version of The Medicines Company’s Angiomax. Dr Reddy’s bivalirudin injection will be available in packages of 10 single-dose vials.
Bivalirudin, a direct thrombin inhibitor, is used to prevent blood clots in people with severe chest pain or other conditions who are undergoing a procedure called angioplasty (to open blocked arteries).
The Angiomax brand and generic had US sales of approximately $ 198 million MAT for the most recent twelve months ending in
